Bioneer Deal May Point To Yuhan R&D Strategy Change
This article was originally published in PharmAsia News
Yuhan has been seen as one of the less aggressive South Korean pharma firms in terms of beefing up R&D. But now, the company may be shifting its strategy as it has decided to become the second biggest shareholder of local bioventure Bioneer, in a move to strengthen its pipeline including immuno-oncology drugs and to diversify into new businesses.
Register for our free email digests: